Question special
Lead Moderator

The efficacy/safety trials of evolocumab and alirocumab suggested there could be adverse effects of either PCSK9 inhibition or low LDL-C levels on cognition. However, there were no signals of adverse effects on cognition in FOURIER or the substudy EBBINGHAUS that performed standardized testing. Any thoughts on the discordance between the earlier phase 3 and FOURIER findings? Are you confident there are no adverse effects on cognition?